TBPH
insider transactionsTheravance Biopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-13.3K
0 buy · 13.3K sell
Net value · 30d
-$218.2K
$0 in · $218.2K out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
3
0 buy · 13.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$109.1K
6.7K sh · $16.39
Own -3%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$54.5K
3.3K sh · $16.38
Own -1%
-
Sell·S
SVP, COMM & MEDICAL AFFAIRS · 10b5-1
$54.6K
3.3K sh · $16.39
Own -1%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +8%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +10%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +8%
-
Grant·A
Director
$0
13.4K sh
Own New
-
Grant·A
Director
$0
6.0K sh
Own +14%
-
Grant·A
Director
$0
46.3K sh
Own +27%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 6.7K | $109.1K |
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 3.3K | $54.5K |
| Jun 15, 2026 | Rhonda Farnum 10b5-1 | Sell S | 3.3K | $54.6K |
| Jun 12, 2026 | Alsup Laurie Smaldone | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Alsup Laurie Smaldone | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Deepika Pakianathan | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Deepika Pakianathan | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Donal O'Connor | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Donal O'Connor | Grant A | 6.0K | $0 |
| Jun 12, 2026 | Susannah Gray | Grant A | 13.4K | $0 |
| Jun 12, 2026 | Susannah Gray | Grant A | 6.0K | $0 |
| May 26, 2026 | Susannah Gray | Grant A | 46.3K | $0 |
About TBPH insider trading
This page tracks insider transactions for Theravance Biopharma, Inc. (TBPH) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.